ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Brings back memories

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 25, 2023 4:00pm

69 Views

Post# 35413190

RE:Brings back memories

That could be part of the reason for today's decent volume after the little reversal yesterday, maybe investors are starting to think about the platform. It's probably nothing, but maybe it's going to rhyme with last July's trading pattern and lead into a long term higher floor.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it